Scholar Rock Holding Corp (SRRK)
26.67
-1.19
(-4.27%)
USD |
NASDAQ |
Nov 21, 16:00
26.69
+0.02
(+0.07%)
After-Hours: 20:00
Scholar Rock Net Income (Quarterly): -64.48M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -64.48M |
| June 30, 2024 | -58.51M |
| March 31, 2024 | -56.85M |
| December 31, 2023 | -46.13M |
| September 30, 2023 | -42.36M |
| June 30, 2023 | -37.92M |
| March 31, 2023 | -39.38M |
| December 31, 2022 | -39.26M |
| September 30, 2022 | -43.30M |
| June 30, 2022 | -44.00M |
| March 31, 2022 | -7.95M |
| December 31, 2021 | -35.91M |
| September 30, 2021 | -37.51M |
| June 30, 2021 | -30.71M |
| March 31, 2021 | -27.67M |
| December 31, 2020 | -26.57M |
| Date | Value |
|---|---|
| September 30, 2020 | -23.56M |
| June 30, 2020 | -19.28M |
| March 31, 2020 | -17.07M |
| December 31, 2019 | -11.57M |
| September 30, 2019 | -16.15M |
| June 30, 2019 | -12.52M |
| March 31, 2019 | -10.76M |
| December 31, 2018 | -14.97M |
| September 30, 2018 | -10.76M |
| June 30, 2018 | -14.71M |
| March 31, 2018 | -8.892M |
| December 31, 2017 | -8.457M |
| September 30, 2017 | -5.929M |
| June 30, 2017 | -5.879M |
| March 31, 2017 | -4.73M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-64.48M
Minimum
Sep 2024
-7.95M
Maximum
Mar 2022
-35.50M
Average
-37.72M
Median
Net Income (Quarterly) Benchmarks
| Cytokinetics Inc | -160.54M |
| Regeneron Pharmaceuticals Inc | 1.341B |
| Ocugen Inc | -12.97M |
| Mirum Pharmaceuticals Inc | -14.24M |
| NeuroBo Pharmaceuticals Inc | -5.652M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 64.78M |
| EPS Diluted (Quarterly) | -0.66 |
| Enterprise Value | 2.408B |
| Earnings Yield | -8.81% |
| Normalized Earnings Yield | -11.40 |